{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for penicillin root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT03943589: Phase 2 Interventional Completed Guillain-Barré Syndrome (GBS)
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:exbivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02449239: Phase 3 Interventional Completed Bladder Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:libivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01959165: Phase 2 Interventional Completed Ulcerative Colitis
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04396717: Phase 1 Interventional Completed Malignant Primary Brain Tumors
(2021)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02306161: Phase 3 Interventional Active, not recruiting Metastatic Ewing Sarcoma
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00785408: Phase 2 Interventional Completed Obesity
(2008)
Source URL:
Class:
PROTEIN
Davalintide (AC-2307) is a second-generation mimetic of a pancreatic peptide hormone amylin, developed by Amylin Pharmaceuticals. In preclinical models, davalintide possessed enhanced pharmacological properties and was able to reduce food intake. Safety, tolerability, and effect on body weight of subcutaneous davalintide were investigated in obese or overweight subjects. The results of the clinical trial were not reported, but Amylin decided to discontinue davalintide in 2010.
Status:
Investigational
Source:
NCT04716231: Phase 3 Interventional Recruiting IgA Nephropathy
(2023)
Source URL:
Class:
PROTEIN
